论文信息 - Phase II Trial of the Anti-CD 19 Bispecific T Cell – Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia - 字舞流文

Phase II Trial of the Anti-CD 19 Bispecific T Cell – Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

H. Einsele | G. Zugmaier | H. Horst | R. Bargou | D. Hoelzer | A. Reichle | M. Brüggemann | N. Gökbuget | M. Stelljes | R. Marks | A. Viardot | C. Faul | M. Topp | S. Alekar | H. Diedrich | S. Neumann | C. Holland | D. Wessiepe | Petra Klappers | Noemi Mergen